Research & Pipeline

A disease may be rare, but its treatment should not be

Catalyst is investing in the science of possibility—discovering, developing, and delivering innovative, life-changing medicines and solutions to transform patients’ lives and address their most important unmet medical needs. It’s all about the company you keep. At Catalyst, we are laser-focused on developing therapies for rare neuromuscular and neurological disorders—we believe this is where we can have the greatest impact on patients’ lives.

Currently, Catalyst is developing amifampridine phosphate for Lambert-Eaton myasthenic syndrome (LEMS) and conducting clinical studies into the following additional therapeutic areas: congenital myasthenic syndromes (CMS), MuSK-positive myasthenia gravis (MuSK-MG), and spinal muscular atrophy (SMA).

Catalyst is also developing a highly potent GABA-aminotransferase (GABA-AT) inhibitor for the treatment of infantile spasms, a rare form of debilitating epileptic seizures that presents in infants.

Amifampridine Phosphate

Business Development

Professional Outreach

Scientific Advisory Board